Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abrysvo + seasonal inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
This coadministration regimen consists of Pfizer's Abrysvo (RSVpreF) and a seasonal inactivated influenza vaccine (SIIV), specifically evaluated in Phase 3 clinical trials using the adjuvanted FLUAD QUADRIVALENT. Abrysvo is a bivalent recombinant protein subunit vaccine composed of stabilized prefusion F glycoproteins from RSV-A and RSV-B subgroups. The influenza component is a quadrivalent inactivated vaccine. This combination is designed for adults aged 65 and older to provide simultaneous protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) and seasonal influenza in a single healthcare visit. Clinical data support the safety and noninferior immunogenicity of concomitant administration compared to sequential administration.
- Brand names
- AbrysvoFLUAD QUADRIVALENT
- Other names
- RSVpreF + SIIV
02
Targets
HA (Hemagglutinin)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on Abrysvo + seasonal inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abrysvo + seasonal inactivated influenza vaccine.